TABLE 3.
Associations between initial (T0-T1) % changes in hormone levels and subsequent (T1-T2) % changes in anthropometrics.
| Model 1 unadjusteda) | Model 2 adjusted for age and sexb) | ||||||
|---|---|---|---|---|---|---|---|
| N | β (95% CI ) | Standardized β | p | β (95% CI ) | Standardized β | p | |
| Dependent variable: T1-T2 ∆ % BMI | |||||||
| T0-T1 ∆ % Leptin | 39 | 0.004 (−0.075; 0.083) | .017 | .917 | 0.011 (−0.068; 0.090) | .046 | .782 |
| T0-T1 ∆ % Insulin | 39 | −0.062 (-0.123; -0.001) | −.319 | .048* | −0.053 (−0.116; 0.011) | −.271 | .102 |
| T0-T1 ∆ % HMW Adiponectin | 39 | 0.097 (−0.008; 0.203) | .293 | .070 | 0.110 (0.000; 0.220) | .332 | .050 |
| T0-T1 ∆ % GIP | 38 | −0.006 (−0.032; 0.021) | −.070 | .675 | 0.000 (−0.028; 0.029) | .006 | .974 |
| T0-T1 ∆ % PP | 38 | −0.032 (−0.090; 0.026) | −.183 | .272 | −0.034 (−0.092; 0.023) | −.195 | .237 |
| T0-T1 ∆ % PYY | 38 | −0.035 (-0.069; -0.002) | −.337 | .039* | −0.032 (−0.068; 0.003) | −.308 | .074 |
| T0-T1 ∆ % CCK | 39 | 0.035 (−0.037; 0.106) | .159 | .333 | 0.014 (−0.064; 0.092) | .064 | .720 |
| T0-T1 ∆ % FGF21 | 38 | −0.021 (-0.040; -0.003) | −.360 | .027* | −0.021 (-0.040; -0.001) | −.350 | .038* |
| T0-T1 ∆ % AgRP | 38 | 0.040 (−0.025; 0.105) | .203 | .221 | 0.023 (−0.050; 0.096) | .115 | .533 |
| Dependent variable: T1-T2 ∆ % WC | |||||||
| T0-T1 ∆ % Leptin | 39 | −0.055 (−0.144; 0.033) | −.205 | .212 | −0.047 (−0.135; 0.042) | −.173 | .290 |
| T0-T1 ∆ % Insulin | 39 | −0.046 (−0.118; 0.027) | −.206 | .209 | −0.033 (−0.107; 0.042) | −.148 | .379 |
| T0-T1 ∆ % HMW Adiponectin | 39 | 0.079 (−0.044; 0.202) | .209 | .201 | 0.103 (−0.024; −0.231) | .274 | .108 |
| T0-T1 ∆ % GIP | 38 | −0.018 (−0.047; 0.011) | −.207 | .213 | −0.015 (−0.045; 0.015) | −.169 | .329 |
| T0-T1 ∆ % PP | 38 | −0.024 (−0.088; 0.040) | −.126 | .449 | −0.027 (−0.091; 0.036) | −.142 | .391 |
| T0-T1 ∆ % PYY | 38 | −0.027 (−0.066; 0.013) | −.224 | .177 | −0.019 (−0.061; 0.023) | −.161 | .359 |
| T0-T1 ∆ % CCK | 39 | −0.009 (−0.091; 0.074) | −.035 | .833 | −0.041 (−0.129; 0.047) | −.164 | .353 |
| T0-T1 ∆ % FGF21 | 38 | −0.015 (−0.037; 0.007) | −.220 | .184 | −0.012 (−0.035; 0.011) | −.175 | .309 |
| T0-T1 ∆ % AgRP | 38 | 0.026 (−0.049; 0.101) | .118 | .481 | 0.001 (−0.082; 0.085) | .006 | .973 |
CI = confidence interval; BMI = body-mass-index, WC = waist circumference; HMW, adiponectin = high-molecular-weight adiponectin, GIP = gastric inhibitory polypeptide; PP = pancreatic polypeptide; PYY = peptide tyrosine-tyrosine; CCK = cholecystokinin, FGF21 = fibroblast growth factor 21, AgRP = agouti-related protein. a) Univariable linear regressions were used with T0-T1% changes in hormone levels as predictor and T0-T2% changes in BMI/WC, as outcomes. b) Adjustment was performed using multiple linear regression.* indicates p < .05 (highlighted in bold text). None of the association was significant at the Bonferroni-corrected significance level α = 0.005.95% CI = 95% Confidence interval.